Loading...
•
Sep 30, 2023
ACADIA Q3 2023 Earnings Report
Acadia reported record revenues driven by the strong DAYBUE launch and growth in the NUPLAZID franchise.
Key Takeaways
Acadia Pharmaceuticals reported record product revenue in Q3 2023, driven by the successful launch of DAYBUE and continued growth of NUPLAZID. The company is also advancing its late-stage pipeline with planned initiations of Phase 3 and Phase 2/Phase 3 studies for ACP-101 and ACP-204, respectively.
Total revenues reached $211.7 million, driven by NUPLAZID and DAYBUE sales.
DAYBUE net product sales were $66.9 million during its first full quarter of commercialization.
NUPLAZID net product sales were $144.8 million, reflecting market share growth.
The company is progressing its pipeline with planned Phase 3 and Phase 2/Phase 3 studies for ACP-101 and ACP-204.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals provided financial guidance for the fourth quarter and full year 2023.
Positive Outlook
- DAYBUE net sales are projected to be in the range of $80 to $87.5 million for the fourth quarter of 2023.
- NUPLAZID net sales are expected to be in the range of $537.5 to $545 million for the full year 2023.
Challenges Ahead
- R&D expense is projected to be in the range of $340 to $350 million for the full year 2023.
- SG&A expense is projected to be in the range of $390 to $400 million for the full year 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income